Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Cambridge, MA, US
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.04% | 1.23M | 0.55% |
| 2 | Schwab U.S. Small-Cap ETF SCHA | 0.01% | 3.19M | 0.03% |
| 3 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 19.8K | 0.06% |
| 4 | Vanguard Russell 2000 ETF VTWO | 0.00% | 198.0K | 0.06% |
| 5 | Schwab U.S. Broad Market ETF SCHB | 0.00% | 455.6K | 0.03% |
| 6 | Vanguard Extended Market ETF VXF | 0.00% | 297.5K | 0.05% |
| 7 | Vanguard Russell 3000 ETF VTHR | 0.00% | 3.8K | 0.06% |
| 8 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.9K | 0.03% |
| 9 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 5.3K | 0.17% |
| 10 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 391.80 | 0.17% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COAG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
